ReviewCancers2023
Hormone Receptor Expression in Meningiomas: A Systematic Review.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
45 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Association of hormone therapy with spheno-orbital meningiomas: bridging evidence and unknowns.Frontiers in oncology · 2026Pooled it
- European Association of Neuro-Oncology guideline on molecular testing of meningiomas for targeted therapy selection.Neuro-oncology · 2025Guideline
- Machine learning for predicting post-operative outcomes in meningiomas: a systematic review and meta-analysis.Acta neurochirurgica · 2024Pooled it
- Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.PloS one · 2024Pooled it
- Review
- A Systematic Review and Meta-Analysis of the Association Between Depot Medroxyprogesterone Acetate and Cerebral Meningioma.Cancers · 2026Review
- Dexamethasone Suppresses Already Low Estrogen Receptor Levels in Meningiomas.International journal of molecular sciences · 2026Review
- Enzalutamide effectively inhibits the growth of meningiomas via p21-dependent senescence induction.Molecular biology reports · 2026Article
- Associations of surgical menopause and hormone replacement therapy with meningioma development.Journal of neuro-oncology · 2026Article
- Hormonal contraceptives and the risk of meningioma: A Swedish register-based case-control study.Neuro-oncology · 2026Article
- Progestogen use and the risk of intracranial meningioma: a systematic review and meta-analysis.EClinicalMedicine · 2026Article
- [Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2026Article
- Trends in meningioma-related mortality among U.S. adults: A CDC WONDER analysis from 2000 to 2023.Surgical neurology international · 2026Article
- Article
- Meningioma regression following depot medroxyprogesterone acetate withdrawal: a case series.BMJ neurology open · 2026Article
- Association of tumor locations, clinical manifestations, and histopathological grade in meningioma: a 10-year single-center study.Frontiers in oncology · 2026Article
- Digital Quantification of Progesterone Receptor Expression in Meningiomas: Associations with WHO Grade and Clinicopathological Features.Turk patoloji dergisi · 2026Article
- Review
- MRI and Meningioma Research: Hotspots and Trends via Bibliometric AnalysisCurrent medical imaging · 2026Article
- Spontaneous Atypical Meningioma in a Pregnant Rhesus Macaque (Macaca mulatta).Journal of medical primatology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Meningiomas are, in most cases, low grade intracranial tumors. However, relapses are frequent. To date, only a few prognostic markers are described in the literature. Several studies have discussed the expression of progesterone, estrogen, androgen, and somatostatin receptors. The utility of analyzing these expressions for prognostic, theragnostic, and therapeutic purposes remains unclear. The aim of this study was to report the expression of these receptors, based on immunohistochemistry. Cochrane Collaboration guidelines and PRISMA statements were followed. We did an online search in PubMed using the MeSH database. References were selected if the investigations occurred from 1990 to 2022. 61 references were included (34 descriptive observational studies, 26 analytical observational studies, and one case report). In this review, we describe the expression of these receptors in function of age, sex, hormonal context, localization, histological subtype, grade, and recurrence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.